Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON30325
NL-OMON30325
Not yet recruiting
Not Applicable

se of combined FDG-PET/CT in diagnosing infectious complications in patients treated with intensive chemotherapy and stem cell transplant recipients for haematological malignancy. - Diagnostic value of FDG-PET/CT in febrile neutropenia

niversitair Medisch Centrum Sint Radboud0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
30
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • •\- admission and treatment at the department of hematology because of a hematological malignancy
  • •\- expected duration of neutropenia \>7 days;and any of the following:
  • •\* C\-reactive proteïn \> 50 mg/l
  • •\* febrile neutropenia \> 3\-4 days despite aimed empirical or aimed antibiotic therapy
  • •\* persistant bacteraemia with coagulase negative Staphylococci
  • •\* pulmonary HRCT inidicated because of suspected pulmonary Aspergillosis

Exclusion Criteria

  • •\- hemodynamic instablility
  • •\- diabetus millitus in which insulin has to be administered within 4 hours of the PET\-scan either bloodglucose levels exceed 15 mmol.l
  • •\- pregnancy or lactation

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Application of FDG-PET/CT for fever of unknown origin: a comparative study to Gallium SPECT
JPRN-UMIN000014657ational Center for Global Health and Medicine180
Recruiting
Not Applicable
FDG-PET and cMRI for the differential diagnosis of parkinson's disease and atypical parkinson syndromsG23.2G23.1G23.9G20Multiple system atrophy, parkinsonian type [MSA-P]Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]Degenerative disease of basal ganglia, unspecifiedParkinson disease
DRKS00016574Klinik für Neurologie und NeurophysiologieUniversitätsklinikum Freiburg314
Completed
Not Applicable
THE CLINICAL VALUE OF COMBINED FDG PET/CT IMAGING IN RESPONSE EVALUATION AFTER RADIOCHEMOTHERAPY IN PATIENTS WITH POTENTIALLY OPERABLE LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
NL-OMON36288Vrije Universiteit Medisch Centrum50
Recruiting
Phase 1
FDG-PET study for pulmonary MAC and CPA
JPRN-jRCTs071190035Takazono Takahiro15
Completed
Not Applicable
Evaluation of Fluorodeoxyglucose Positron Emission Tomography (F18-FDG PET) scans in infection of the extremitiesInfection of the extremitiesInfection - Studies of infection and infectious agents
ACTRN12612000479808Sir Charles Gairdner Hospital30